Compare LZB & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | ZYME |
|---|---|---|
| Founded | 1927 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1994 | 2022 |
| Metric | LZB | ZYME |
|---|---|---|
| Price | $39.63 | $26.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $39.00 | $38.90 |
| AVG Volume (30 Days) | ★ 743.9K | 625.2K |
| Earning Date | 06-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | 5.11 | ★ 33.33 |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $2,349,433,000.00 | $105,965,000.00 |
| Revenue This Year | $1.89 | $183.10 |
| Revenue Next Year | $2.09 | N/A |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $29.03 | $11.86 |
| 52 Week High | $44.90 | $29.75 |
| Indicator | LZB | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 59.90 |
| Support Level | $36.31 | $22.44 |
| Resistance Level | $39.76 | $26.75 |
| Average True Range (ATR) | 1.73 | 1.10 |
| MACD | -0.01 | 0.35 |
| Stochastic Oscillator | 46.29 | 71.80 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.